Warning ! The cookie feature is disabled in your browser. Some features may not work properly.
Click here to learn how to activate your cookies. |
|
29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID)
|
|
|
|
Webcasted Presentation
|
|
|
|
|
IMPACT OF A ROTAVIRUS VACCINATION CAMPAIGN ON HOSPITALISATIONS IN FRANCE : THIRD -YEAR SURVEY OF THE IVANHOE STUDY
Canada 
Disclosure : Grant support
Brest University Hospital sponsored the study. Sanofi-Pasteur MSD provided vaccine and funded the study. Sanofi-Pasteur did not play any role in the study design, collection, analysis, or interpretation of data.
Dr Gagneur has received research grants from pharmaceutical companies including Pfizer, Merck, Sanofi-Pasteur MSD.
[More]
[Less]
9 slide(s) – English – 2011-06-07
Impact of a rotavirus vaccination campaign on hospitalisations in France : Third –year survey of the IVANHOE study
Gagneur A, Nowak E, Segura JF, Delaperrière N, Abalea L, Poulhazan E, Morvan F, Auzanneau L, Jossens A, Lemaitre T, Payan Ch, Jay N, Oger E and the group of investigators
Objective
To determine the real-world impact of rotavirus vaccination, controlling for epidemic-to-epidemic variation in disease burden.
Methods
An active hospital-based surveillance system initiated 5 years before vaccine introduction (May 2007) enabled the occurrence of acute rotavirus diarrhoea (ARD) to be modelled. Inclusion in a poisson regression model of an indicator variable for vaccination quantified the impact of a vaccination campaign with Rotateq offered to all children born in Brest by paediatricians, mother and child health centres and general practitioners from the Brest Urban Community (BUC). The principal endpoint was the number of hospitalisations for ARD in infants under 3 years old living in the BUC during 2009/2010 epidemic season.
Results
More than 7150 infants received at least one dose. Vaccine coverage was 55% and 51% for one and 3 doses respectively. Timely administration of doses 1 and 3 was respected in 97% of cases.
Modelling allows estimating that number of hospitalizations for ARD has been divided by 2,8 (95% CI: 2,2 – 3,5) during the last epidemic season (2009/2010). The observed number of cases was 40 whereas the expected number was 110. Comparatively, in the previous 2008/2009 season the number of hospitalizations has been divided by 1,8 (95% CI: 1,5-2,2).
Relative risk reduction for ARD hospitalization was 95% (95% CI: 87% - 98%).
Conclusion
We observed an increasing impact of rotavirus vaccination on hospitalization in the third year survey on this vaccination campaign.
|
|
|
|
